Progress of diagnosis and treatment of high-risk chronic lymphocytic leukemia / 肿瘤研究与临床

ABSTRACT

Chronic lymphocytic leukemia (CLL) is a malignant disease of the lymphatic and hematopoietic systems with monoclonal and mature small lymphocytes. Although CLL is an indolent leukemia, its clinical outcome is highly heterogeneous, the high-risk patients have a rapid clinical progression, and are prone to relapse and drug resistance, and have a short survival time. Therefore, it is particularly important to accurately judge the prognosis of patients and carry out the stratified treatment. In recent years, although the combination of immunochemotherapy and ibrutinib has a good effect on the overall CLL patients, the clinical efficacy for high-risk CLL patients is still not satisfactory. This article mainly reviews the changes in the diagnosis of high-risk CLL and the treatment progress in the era of novel agents.